Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Nuclear Medicine Radiation Equipment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nuclear Medicine Radiation Equipment market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nuclear medicine physicians, oncologists, and hospital radiology administrators, the precise detection and quantification of functional abnormalities at the molecular level remains a critical diagnostic gap. Conventional anatomical imaging (CT, MRI) reveals structural changes only after disease progression, often missing early metabolic or receptor-level alterations. Nuclear medicine radiation equipment directly addresses this pain point by enabling molecular imaging and targeted radiotherapy—detecting gamma or positron emissions from radiopharmaceuticals that accumulate in specific tissues (tumors, inflamed sites, or organ-specific receptors). These technologies facilitate earlier cancer diagnosis, personalized therapy monitoring, and minimally invasive treatment delivery. The global market for Nuclear Medicine Radiation Equipment was estimated to be worth US648millionin2025andisprojectedtoreachUS648millionin2025andisprojectedtoreachUS 855 million, growing at a CAGR of 4.1% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6092454/nuclear-medicine-radiation-equipment
Defining Nuclear Medicine Radiation Equipment: From Detection to Therapy
Nuclear medicine radiation equipment refers to specialized medical devices that utilize radioactive materials (radiopharmaceuticals) for the diagnosis and treatment of diseases, primarily cancers and certain organ disorders (e.g., thyroid, cardiac, neurological). These devices are designed to detect gamma or positron radiation emitted by radiopharmaceuticals introduced into the body (via injection, ingestion, or inhalation) or to deliver targeted radiation to specific tissues. Unlike conventional X-ray or CT systems that generate images based on tissue density, nuclear medicine equipment captures molecular imaging data—physiological and biochemical processes at the cellular level. The two principal technology categories are SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography), both of which can be integrated with CT (SPECT/CT, PET/CT) or MRI (PET/MR) for hybrid anatomical-functional correlation. Key performance metrics include system sensitivity (counts per second per microcurie), spatial resolution (millimeters, typically 4-6 mm for clinical PET systems), and time-of-flight (TOF) capability for improved signal-to-noise ratio in PET.
Market Segmentation by Technology: SPECT, PET, and Emerging Hybrid Systems
The Nuclear Medicine Radiation Equipment market is segmented by imaging modality, each serving distinct clinical niches:
- SPECT Systems (Volume-Dominant Segment, ~48% of 2025 market): SPECT cameras (gamma cameras with rotating detectors) acquire multiple planar projections to reconstruct three-dimensional radiotracer distribution. SPECT is widely deployed for myocardial perfusion imaging (MPI) in coronary artery disease, bone scintigraphy for metastasis detection, and neuroendocrine tumor localization (e.g., using 111In-pentetreotide). According to Q4 2025 industry data, SPECT accounts for approximately 48% of global unit installations, with average system pricing ranging from US250,000toUS250,000toUS 600,000 for two-headed systems. A key development in H1 2026 is the accelerated replacement of conventional sodium iodide (NaI) detectors with cadmium-zinc-telluride (CZT) solid-state detectors. CZT-based SPECT systems (e.g., Spectrum Dynamics’ D-SPECT, GE HealthCare’s NM/CT 870 CZT) offer 3-5x higher sensitivity and 2x better energy resolution (5% vs. 9-10% at 140 keV), enabling reduced acquisition times (from 15-20 minutes to 4-6 minutes for MPI) and lower patient radiation exposure. However, CZT systems command a 25-35% price premium, limiting adoption to high-volume cardiology centers in North America and Europe.
- PET Systems (Fastest-Growing Segment, Projected 5.2% CAGR 2026-2032): PET detects coincident gamma photons from positron-emitting radiotracers, predominantly 18F-FDG (fluorodeoxyglucose) for oncology metabolic imaging. PET holds advantages in sensitivity (10-100x higher than SPECT) and quantitative accuracy (SUV, standardized uptake value). The PET segment is driven by four concurrent trends: (1) Expansion of total-body PET systems (e.g., Siemens Biograph Vision Quadra, 106 cm axial field-of-view) enabling 30-second whole-body scans and delayed imaging out to 6-8 half-lives; (2) Integration with MRI (simultaneous PET/MR) for neurology and prostate oncology applications requiring soft-tissue contrast unavailable from CT; (3) Adoption of digital silicon photomultipliers (SiPMs) achieving 200-300 ps time-of-flight resolution, improving image contrast by 25-35% compared to analog PMTs; and (4) Emerging radiotracers beyond FDG (e.g., 68Ga-DOTATATE for neuroendocrine tumors, 18F-fluciclovine for recurrent prostate cancer, 18F-PI-2620 for tau imaging in Alzheimer’s disease). A notable market dynamic from Q1 2026: Chinese PET/CT installations grew 22% year-over-year, driven by provincial reimbursement expansions (e.g., Guangdong province added 8 oncology PET indications to basic medical insurance in December 2025).
- Others (Standalone Gamma Probes and Intraoperative Systems): Includes hand-held gamma detection probes for radioguided surgery (e.g., sentinel lymph node biopsy in melanoma or breast cancer), thyroid uptake probes, and intraoperative beta probes. This segment represents ~8% of market value but is essential for emerging theragnostic procedures (e.g., 68Ga- or 177Lu-labeled radiopharmaceuticals requiring intraoperative confirmation of tumor margins).
Application Landscape: Hospitals, Academic Research Centers, and Emerging Theranostic Centers
- Hospitals (Dominant End-User, ~78% of 2025 market): Tertiary care hospitals and comprehensive cancer centers account for the majority of nuclear medicine equipment installations. A key trend in 2025-2026 is the expansion of theranostic clinics—dedicated units that pair diagnostic imaging (using PET/CT or SPECT/CT) with subsequent radioligand therapy (RLT) using beta- or alpha-emitting isotopes (e.g., 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, FDA approved March 2024; 161Tb-PSMA in clinical trials as of Q1 2026). This “see and treat” paradigm concentrates equipment demand, as centers require both imaging-capable gamma cameras and dose-calibration/administration infrastructure.
- Academic and Research Centers (Innovation Driver): University hospitals and research institutes drive adoption of emerging technologies—total-body PET (UC Davis Explorer system), dedicated breast PET (POSITrigo’s PET mammography system, FDA breakthrough device designation September 2025), and preclinical multi-modality imaging (PET/CT/SPECT/OI for small animal studies). Research demand is fueled by NIH and Horizon Europe grant funding designated for molecular imaging biomarker development.
- Other (Radiopharmaceutical Production Facilities and CROs): Equipment used for quality control (gamma spectroscopy) and biodistribution studies (murine SPECT/PET) by contract research organizations supporting pharmaceutical radiotracer development.
Competitive Landscape and Exclusive Market Observation (2025–2026)
Key Players: Hermes Medical Solutions (nuclear medicine image processing software), DOSIsoft (dosimetry planning), Segami (workstation software), GE HealthCare (Discovery NM/CT series, Omni Legend PET/CT), Siemens Healthineers (Biograph series, Symbia SPECT), Philips (Vereos PET/CT), Mirion Technologies (radiation detection and shielding), Comecer (radiopharmacy hot cells and dose calibrators), Syntermed (advanced cardiac quantification), UltraSPECT (collimator design optimization), LabLogic Systems (radiolabeling and QC instruments), Mediso (multi-modality preclinical and clinical SPECT/PET), CANON MEDICAL SYSTEMS CORPORATION (Celesteion PET/CT), Catalyst Medtech (pharmaceutical delivery optimization), Lemer Pax (radiation shielding), Spectrum Dynamics Medical (D-SPECT CZT cameras), Brainlab (stereotactic localization), Mirada Medical (image segmentation and registration), Trasis (automated radiotracer synthesizers), SOFIE (radiopharmaceutical manufacturing and distribution), ITM Isotope Technologies Munich (nuclear medicine R&D platform), Positrigo (dedicated organ-specific PET systems), PAIRE (augmented reality guidance for nuclear procedures), Neusoft Medical Systems Co., Ltd. (Chinese domestic PET/CT manufacturer).
Exclusive Industry Insight (H1 2026): A strategic polarization has emerged between full-field integrated imaging giants (GE, Siemens, Philips, Canon) and specialized solution providers (Spectrum Dynamics, Positrigo, Mediso). The integrated vendors compete on installed base and service networks, offering complete radiology suites (PET/CT + MRI + CT + interventional) to large hospital systems at bundled capital equipment prices. Their 2025 performance shows flat-to-single-digit growth in mature markets but double-digit expansion in China and India. Conversely, specialized vendors target specific clinical frustrations: Spectrum Dynamics’ CZT-based cardiac SPECT (D-SPECT) captures a beating-heart volume in 2-4 minutes with <2 mSv radiation dose (versus 10-15 mSv for conventional SPECT MPI), solving the dual demand for patient throughput and ALARA compliance. Positrigo’s NeuroLF (brain-dedicated PET, projected 2027 FDA submission) aims to offer 1.5 mm spatial resolution for early dementia diagnosis at one-third the cost of general-purpose PET/CT. Notably, the Chinese domestic champion Neusoft Medical has captured ~15% of China’s PET/CT new installation market (up from 7% in 2022), leveraging provincial regulatory preferences for domestically manufactured high-end devices under the “Medical Device Localization Acceleration Plan” (NDRC Document No. 82, 2025). Neusoft’s Aurora PET/CT (128-slice CT, 24 cm axial PET) competed successfully in H2 2025 procurement tenders against GE and Siemens in 12 provincial-level hospitals, primarily on price (20-25% discount) and domestically sourced SiPM arrays.
Technical Deep Dive: Time-of-Flight PET and the Sensitivity Image Quality Trade-off
A fundamental performance barrier in PET imaging is the random coincidence fraction—false event pairs from unrelated annihilation photons that degrade image contrast and quantification accuracy. Time-of-flight (TOF) PET addresses this by measuring the arrival time difference (Δt) of the two annihilation photons with picosecond precision. Using the relation Δx = c·Δt/2, TOF localizes the emission event along the line-of-response (LOR) to within 20-30 mm (current commercial systems with 200-300 ps timing resolution), reducing the effective random fraction by 50-70% compared to non-TOF systems. The engineering challenge lies in detector speed: achieving ≤200 ps resolution requires silicon photomultipliers (SiPMs) paired with fast scintillators (e.g., LYSO or LSO, decay time 40-50 ns). Recent advances from Siemens (Biograph Vision, 210 ps TOF resolution, January 2025 specification update) and GE (55 ps TOF in prototype, disclosures at SNMMI 2025) approach the physical limit (~10 ps, governed by annihilation photon jitter). However, the clinical benefit of sub-100 ps TOF beyond improved contrast-to-noise ratio (CNR) remains debated: simulation studies suggest diminishing returns below 150 ps for standard whole-body FDG scans, with benefit concentrated in high-BMI patients (scatter fraction >45%) and low-count protocols (e.g., pediatric or dynamic imaging). For equipment buyers, the practical implication is that premium TOF performance (>300 ps) commands 15-25% higher system cost without proportional diagnostic accuracy improvements in most general oncology applications—suggesting value-based purchasing favors mid-range TOF (250-300 ps) systems.
Future Outlook (2026–2032): Drivers, Policy Tailwinds, and Emerging Technologies
Growth Drivers:
- Theranostics expansion: FDA approvals of 177Lu-DOTATATE (2018) and 177Lu-PSMA-617 (2022), with 161Tb-based and 225Ac-based radiopharmaceuticals in advanced clinical trials (68Ga/177Lu-theragnostic pairs), will drive demand for quantitative SPECT/PET imaging for patient selection and treatment response monitoring.
- Aging demographics and rising cancer incidence: Global cancer cases projected to reach 25 million annually by 2030 (GLOBOCAN 2025 estimate). Molecular imaging is increasingly incorporated into clinical guidelines—ESMO 2026 updates recommend PSMA PET/CT as first-line staging for high-risk prostate cancer, a change expected to increase PET/CT utilization by 40% in member countries.
- Emerging radiotracers: FDA’s 2025 guidance on microdose radiopharmaceutical development (enabling first-in-human studies with <10 µg tracer mass, significantly reducing toxicology requirements) will accelerate novel tracer development (tau imaging, fibroblast activation protein (FAP) inhibitors, CXCR4-targeted tracers), creating new clinical indications for installed equipment.
Constraints: Radiopharmaceutical supply chain fragility (dependence on cyclotron networks for 18F, 68Ge/68Ga generators, and nuclear reactors for 99Mo/99mTc); high capital acquisition costs (PET/CT systems range from US$ 1.2-3.5 million); and the specialist workforce shortage—the American College of Nuclear Medicine reported a 20% vacancy rate for board-certified nuclear medicine physicians in 2025, limiting scanner utilization in community practice settings.
The report projects that hybrid systems (PET/CT and SPECT/CT) will exceed 85% of new installations by 2028, driven by clinical preference for fused anatomical-functional data and declining cost deltas between standalone and hybrid configurations. Asia-Pacific will exhibit the fastest growth (projected 6.5% CAGR 2026-2032), led by China’s Nuclear Medicine Development Plan (2025-2030, targeting 5,000 PET/CT units by 2030 versus approximately 1,400 units in early 2025), and India’s National Medical Device Policy 2025 (which reduces import tariffs on nuclear medicine equipment from 15% to 7.5%).
Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
